ED
Earl Martin Douglas
SVP, General Counsel

Earl Martin Douglas insider trades: Allogene Therapeutics (ALLO) stock buys and sales

SVP, General Counsel, Allogene Therapeutics Last trade Aug 21, 2026 24 Form 4 filings
$103K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2008
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Earl reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 21, 2026ALLO↓ Sell$63K
Feb 2, 2026ALLO↓ Sell$40K
Feb 3, 2025ALLO↓ Sell$11K
Mar 28, 2012BMTI↓ Sell$126K
Oct 14, 2011BMTI↓ Sell$27K
Oct 11, 2011BMTI↓ Sell$36K
Oct 5, 2011BMTI↓ Sell$26K
Mar 17, 2010BMTI↓ Sell$67K
Jan 13, 2010BMTI↓ Sell$155K
Mar 17, 2009BMTI↓ Sell$10K
Mar 28, 2008BMTI↑ Buy$9K
Jan 23, 2008BMTI↑ Buy$53K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ALLO insiders

Open-market trades in the last 12 months

About Earl Martin Douglas's insider trades

Earl Martin Douglas is SVP, General Counsel at Allogene Therapeutics (ALLO). Since Jan 23, 2008, Earl has reported 2 open-market purchases worth $63K and 10 sales worth $561K on SEC Form 4. In the last 12 months: 2 sales ($103K).

Their filings also include grants and awards (11 filings), shares withheld for taxes (3 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALLO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.